In the present study, mTOR was positive in 65.9% of patients who underwent LDLT for HCC in the group, and Ang‐2 levels were significantly higher in the mTOR‐positive group than mTOR‐negative group. The gene discussed is MTOR; the disease is hepatocellular carcinoma.